- AbbVie (ABBV, Financial) to present critical new data from its oncology portfolio at ASCO 2025.
- Highlight includes 63% objective response rate for telisotuzumab adizutecan in EGFR-mutated NSCLC patients.
- ABBV-706 and Pivekimab sunirine (PVEK) show promising response rates in challenging tumor types.
AbbVie (ABBV) will showcase significant advancements from its oncology pipeline at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, taking place from May 30 to June 3. The company is set to present data on some of their cutting-edge antibody-drug conjugates (ADCs), which reflect AbbVie's strategic focus on difficult-to-treat cancers.
Among the highlights is telisotuzumab adizutecan (Temab-A), which achieved a 63% objective response rate in pre-treated epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) patients. Notably, 54% of responders maintained their response for six months or longer. This efficacy was observed regardless of c-Met protein expression, signaling potential for broader application.
ABBV-706, another investigational ADC, yielded a 31.3% objective response rate in patients with high-grade neuroendocrine neoplasms, a rare and aggressive tumor type, with a median duration of response lasting 5.6 months. The trial underscored ABBV-706's potential in areas with limited treatment options.
In blastic plasmacytoid dendritic cell neoplasm (BPDCN), a highly aggressive blood cancer, Pivekimab sunirine (PVEK) demonstrated a 70% composite complete response rate in untreated patients, with the median duration of response reaching 9.8 months. For relapsed or refractory cases, the response rate was lower at 14%.
The investigational ADCs presented at ASCO 2025 are part of AbbVie's broader commitment to enhancing cancer treatment. These therapies are undergoing further clinical evaluation to better understand their full potential and safety profiles, as showcased by the reported manageable side effects commonly associated with ADCs.
AbbVie remains focused on advancing these candidates through various clinical trials, including those in combination with other immunotherapies, underscoring their commitment to developing innovative treatments for challenging malignancies.
